A phase 3 clinical trial recently reported in The Lancet demonstrated that the monoclonal antibody drug dupilumab significantly reduced the symptoms of eczema in children between the ages of 6 months and 5 years old when administered in conjunction with a topical corticosteroid.

Dupilumab′s safety and effectiveness were assessed in phase 3 clinical trial on 162 kids with uncontrolled moderate-to-severe atopic dermatitis between 6 months and 5 years.

The study participants either received an injection of the drug and a topical corticosteroid of low potency every four weeks or only a topical corticosteroid in the placebo group.

According to researchers, more than half of the patients getting dupilumab showed 75% improvement in their Eczema Area and Severity Index (EASI-75) after 16 weeks of treatment. The EASI-75 is a scale used by medical practitioners to assess the quantity and severity of inflammatory lesions on the body.

Additionally, after 16 weeks of treatment with dupilumab, researchers discovered that 28% of patients had clean or clear skin, and 48% had a decrease in itching. Some minor side effects, such as conjunctivitis/dry eye condition, were common, and overall the safety profile was very good, but more studies were necessary for dupilumab.

(Source: https://www.medicalnewstoday.com/articles/new-drug-helped-reduce-eczema-in-75-in-infants-and-young-children#What-is-dupilumab?)